glp-1 san diego China approval for Eli Lilly pill to come as soon as 2026, executive says A new study from UC

Updated May 2025

Key factors include: Long and expensive medication development Complex peptide and injectable manufacturing Limited direct competition during patent protection Insurance and prior-authorization rules Deductibles, copays and coinsurance Rapidly growing demand Patients should compare current coverage, pharmacy prices, manufacturer programs and medically appropriate options with their healthcare provider

Weight Loss: Whats Different

The researchers analyzed data from a 2025 survey of 7,521 adults in the United States

The cost of independent testing is minimal compared to the cost of a compromised study

The program covers three FDA-approved GLP-1 weight-loss medications through a centralized Medicare process separate from standard Part D drug coverage: Wegovy (injectable and tablet formulations) Zepbound (KwikPen only) Foundayo (oral formulation) To be eligible, patients must be enrolled in a Medicare Part D plan and meet BMI and health criteria